VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Akero Therapeutics Executive Compensation (FY24)

AKRO · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Andrew Cheng
Latest say-on-pay support
=
June 3, 2025
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Akero Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 4, 2025
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Akero Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
245 figures on this page: 241 cited to the filing that reported them, 4 calculated from figures it prints. See the citations

More on Akero Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Cheng: $8,834,907 → $10,465,855 (18.5% higher)
Say-on-pay support: 95.4% → 98.1% (2.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Akero Therapeutics' chief executive and what were they paid?
Andrew Cheng was paid $10,465,855 in total compensation as President and Chief Executive Officer for fiscal 2024. Cheng's total was 18.5% higher than the $8,834,907 reported for fiscal 2023.
What was Akero Therapeutics' say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 98.1% of votes cast for or against in favor at the meeting held June 3, 2025.
Which companies are in Akero Therapeutics' peer group?
The disclosed peer group names Aclaris Therapeutics, Inc., AnaptysBio, Inc., Crinetics Pharmaceuticals, Inc., Kura Oncology, Inc. and Madrigal Pharmaceuticals, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Cheng
President and Chief Executive Officer
◇—◇◇◇——◇
William (PFO)
Chief Financial Officer
◇—◇◇◇——◇
Jonathan Young
Chief Operating Officer
◇—◇◇◇——◇
Catriona Yale
Chief Development Officer
◇—◇◇◇——◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Cheng
President and Chief Executive Officer
◇—◇◇◇——◇
William White
Chief Financial Officer
◇—◇◇◇——◇
Timothy Rolph
Chief Scientific Officer
◇—◇◇◇——◇
Catriona Yale
Chief Development Officer
◇—◇◇◇——◇
Jonathan Young
Chief Operating Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Cheng
President and Chief Executive Officer
◇—◇◇◇——◇
Scott Gangloff
Chief Technology Officer
◇—◇◇◇——◇
William White
Chief Financial Officer
◇—◇◇◇——◇
Catriona Yale
Chief Development Officer
◇—◇◇◇——◇
Jonathan Young
Chief Operating Officer
◇—◇◇◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew ChengRSU◇——◇——◇
Andrew ChengOPTION◇——◇—◇◇
Catriona YaleRSU◇——◇——◇
Catriona YaleOPTION◇——◇—◇◇
Jonathan YoungRSU◇——◇——◇
Jonathan YoungOPTION◇——◇—◇◇
Scott GangloffRSU◇——◇——◇
Scott GangloffOPTION◇——◇—◇◇
Scott GangloffOPTION◇——◇—◇◇
William WhiteOPTION◇——◇—◇◇
William WhiteRSU◇——◇——◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Andrew ChengOption◇—◇12/08/33
Option◇—◇12/16/34
Option◇—◇12/09/32
RSU◇◇——
RSU◇◇——
Option◇—◇12/08/31
RSU◇◇——
Scott GangloffOption◇—◇4/29/1934
Option◇—◇12/16/34
RSU◇◇——
Jonathan YoungOption◇—◇12/08/33
Option◇—◇12/16/34
Option◇—◇12/09/32
RSU◇◇——
RSU◇◇——
Option◇—◇12/08/31
RSU◇◇——
Catriona YaleOption◇—◇12/08/33
Option◇—◇12/16/34
Option◇—◇12/09/32
RSU◇◇——
RSU◇◇——
Option◇—◇12/08/31
RSU◇◇——
William WhiteOption◇—◇12/08/33
Option◇—◇12/16/34
Option◇—◇11/09/33
Option◇—◇12/09/32
RSU◇◇——
RSU◇◇——
Option◇—◇12/08/31
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Andrew Cheng
President and Chief Executive Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Catriona Yale
Chief Development Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Jonathan Young
Chief Operating Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Scott Gangloff
Chief Technology Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
William White
Chief Financial Officer · Employment agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark T. Iwicki
◇—◇———◇
Jane Henderson
◇—◇———◇
Tomas Heyman
◇—◇———◇
Graham L. Walmsley
◇—◇———◇
Yuan Xu
◇—◇———◇
Judy Chou
◇—◇———◇
Seth L. Harrison
◇—◇———◇
Andrew Cheng served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Aclaris Therapeutics, Inc. ACRS
  • AnaptysBio, Inc. ANAB
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Kura Oncology, Inc. KURA
  • Madrigal Pharmaceuticals, Inc. MDGL
  • MannKind Corporation MNKD
  • Mirum Pharmaceuticals, Inc. MIRM
  • Morphic Holding, Inc. MOR
  • RAPT Therapeutics, Inc. RAPT
  • REGENXBIO Inc. RGNX
  • Replimune Group, Inc. REPL
  • Syndax Pharmaceuticals, Inc. SNDX
  • Terns Pharmaceuticals, Inc. TERN
  • Tyra Biosciences, Inc. TYRA
  • Ventyx Biosciences, Inc. VTYX
  • Viking Therapeutics, Inc. VKTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 3, 2025=◇◇◇
2023April 10, 2024=◇◇◇
2022June 23, 2023=◇◇◇
2021June 2, 2022=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Andrew Cheng (President and Chief Executive Officer), FY2024 total compensation $10,465,855 (base salary $686,000) [exec_comp, SEC accession 0000950170-25-058964, filed 2025-04-28]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Akero Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Akero Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Akero Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Akero Therapeutics' disclosed peer group is defensible, who names Akero Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
245 figures on this page: 241 cited to the filing that reported them, 4 calculated from figures it prints.
241 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001193125-25-134883
    Proposal 1 at the Annual Meeting.
  2. 0000950170-25-058964
    Director Compensation · EXECUTIVE COMPENSATION TABLES · Grants of Plan-Based Awards · Potential Payments Upon Termination
  3. 0001193125-24-160069
    Proposal 1 at the Annual Meeting.
  4. 0000950170-24-049210
  5. 0001193125-23-175032
    Proposal 1 at the Annual Meeting.
  6. 0000950170-23-015896
    EXECUTIVE COMPENSATION TABLES
  7. 0001193125-22-167309
    Proposal 1 at the Annual Meeting.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Akero Therapeutics executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/AKRO (accessed 2026).
Short form: data: Velarion

The paid brief for Akero Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Akero Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Akero Therapeutics discloses

The companies named in AKRO's own disclosed peer group.

Aclaris Therapeutics, Inc.AnaptysBio, Inc.Crinetics Pharmaceuticals, Inc.Kura Oncology, Inc.Madrigal Pharmaceuticals, Inc.MannKind CorporationMirum Pharmaceuticals, Inc.RAPT Therapeutics, Inc.REGENXBIO Inc.Replimune Group, Inc.Syndax Pharmaceuticals, Inc.Terns Pharmaceuticals, Inc.Tyra Biosciences, Inc.Ventyx Biosciences, Inc.Viking Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy